Get started
Author

Luca De Rosa

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials
1998 · Stefano Pasquali, J D Maqueo, et al. · Journal of Clinical Oncology · 470
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
2010 · Sara Bringhen, Alessandra Larocca, et al. · Blood · 382
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
2010 · Marco Ladetto, Gloria Pagliano, et al. · Journal of Clinical Oncology · 267
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
2018 · Meletios A Dimopoulos, Francesca Gay, et al. · The Lancet · 237
PDF
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial
2022 · Roberto Mina, Pellegrino Musto, et al. · The Lancet Oncology · 90
PDF
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival
2014 · S Ferrero, M Ladetto, et al. · Leukemia · 85
Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
2012 · Giuseppina Bonanno, Andrea Mariotti, et al. · Journal of Translational Medicine · 67
PDF
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma
2016 · A Larocca, S Bringhen, et al. · Leukemia · 45
Alpha‐2a‐interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma
1990 · Aldo Montuoro, Luca De Rosa, et al. · British Journal of Haematology · 45
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial
2019 · Sara Bringhen, Mattia D’Agostino, et al. · Haematologica · 44
Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial)
2016 · Pieter Sonneveld, Meral Beksac, et al. · Blood · 35
Haemopoietic reconstitution after autologous blood stem cell transplantation in patients with malignancies: a multicentre retrospective study
1994 · Luca Pierelli, Antonio Iacone, et al. · British Journal of Haematology · 35
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients
2013 · Alessandra Larocca, Sara Bringhen, et al. · Blood · 26
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients
2014 · Alberto Rocci, Manuela Gambella, et al. · British Journal of Haematology · 21
PDF
Bortezomib, Melphalan, Prednisone and Thalidomide Followed by Maintenance with Bortezomib and Thalidomide (VMPT-VT) for Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of Prognostic Factors
2010 · Antonio Palumbo, Sara Bringhen, et al. · Blood · 21
A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens.
2009 · Antonio Palumbo, Michele Cavo, et al. · Blood · 21
Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party
2020 · Ali Bazarbachi, Myriam Labopin, et al. · Transplantation and Cellular Therapy · 19
Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients.
2007 · Marco Ladetto, Gloria Pagliano, et al. · Blood · 18
Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form
2012 · Angela Rago, Sara Grammatico, et al. · Cancer · 16
Cisplatin-paclitaxel weekly schedule in advanced solid tumors: A phase I study
1997 · G. Frasci, P. Comella, et al. · Annals of Oncology · 16
Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer
2002 · A Perillo, L Pierelli, et al. · Bone Marrow Transplantation · 15
Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission
2002 · L. De Rosa, Lalle M., et al. · Annals of Hematology · 14
Therapy of ‘high risk’ myelodysplastic syndromes with an association of low-dose Ara-C, retinoic acid and 1, 25-dihydroxyvitamin D3
1992 · L De Rosa, A Montuoro, et al. · Biomedicine & Pharmacotherapy · 13
Hemopoietic Recovery and Infectious Complications in Breast Cancer and Multiple Myeloma after Autologous CD34+ Cell-Selected Peripheral Blood Progenitor Cell Transplantation
2004 · Luca De Rosa, Gabriel Anghel, et al. · International Journal of Hematology · 12
Detection of Breast Cancer Cells in the Bone Marrow or Peripheral Blood: Methods and Prognostic Significance
2000 · Maurizio Lalle, Luca De Rosa, et al. · Tumori Journal · 12
Works count: 63
Citation count: 2,160
H-index: 18
I10-index: 26
Year
Topic
Type